Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (528 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-05-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: chronicseveretolerabilitythe treatmentmalignancy
  Phrases that lowered it: visitevaluate theto evaluateasthmamale
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 1531 (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 129 (lowers risk) · Sponsor's track record
• Sponsor's past termination rate: 8.0% (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Maximum age: 81 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Minimum age: 13 (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma NCT05274815 · started 2022 · scored riskier than 9% of active trials completed
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma NCT03347279 · started 2017 · scored riskier than 7% of active trials completed
• Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma NCT05398263 · started 2022 · scored riskier than 11% of active trials terminated
• Safety Study in Adolescent and Adult Patients With Asthma NCT01476904 · started 2011 · scored riskier than 14% of active trials completed
• Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma NCT03927157 · started 2019 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.